Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INMUNOCEM-OA for Knee Osteoarthritis
NCT05936060Phase 2Not yet recruiting
- Sponsor
- Curexsys
- Start
- Oct 2023
- Primary completion
- Jul 2026
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 2, randomised, double-blind trial of INMUNOCEM in knee osteoarthritis (OA) (2 arms), sponsored by Curexsys. Primary endpoints: Visual Analogue Scale at 30 months, Knee Injury and Osteoarthritis Outcome Score at 30 months and 1 more. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
INMUNOCEM
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05936060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936060.